title: Usefulness of rosuvastatin to prevent periprocedural myocardial injury in patients undergoing elective coronary intervention.
abstract: The aim of the present study was to investigate whether percutaneous coronary intervention-related periprocedural myocardial infarction (MI) can be suppressed more significantly with high- compared with low-dose rosuvastatin. A total of 232 patients scheduled to undergo elective percutaneous coronary intervention within 5 to 7 days were assigned to groups that would receive either 2.5 or 20 mg/day of rosuvastatin (n = 116 each). The incidence of periprocedural MI did not significantly differ between the high and low-dose groups (8.7% vs 18.7%, p = 0.052). In patients who were not taking statins at the time of enrollment, high-dose rosuvastatin significantly suppressed periprocedural MI compared with the low dose (10.5% vs 30.0%, p = 0.037). The difference was not significant in patients who were already taking statins (high vs low dose 7.6% vs 10.6%, p = 0.582). In conclusion, the incidence of percutaneous coronary intervention-related periprocedural MI was reduced more effectively by high-dose than by low-dose rosuvastatin in statin-naive patients. However, low-dose rosuvastatin is sufficient for patients who are already taking statins.
authors.affiliation: Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan. htakano@nms.ac.jp
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Takano
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Ohba
authors.forename: Eisei
authors.initials: E
authors.lastname: Yamamoto
authors.forename: Hideki
authors.initials: H
authors.lastname: Miyachi
authors.forename: Keisuke
authors.initials: K
authors.lastname: Inui
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Kawanaka
authors.forename: Masataka
authors.initials: M
authors.lastname: Kamiya
authors.forename: Arifumi
authors.initials: A
authors.lastname: Kikuchi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Jun
authors.initials: J
authors.lastname: Tanabe
authors.forename: Shigenobu
authors.initials: S
authors.lastname: Inami
authors.forename: Gen
authors.initials: G
authors.lastname: Takagi
authors.forename: Kuniya
authors.initials: K
authors.lastname: Asai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yasutake
authors.forename: Chikao
authors.initials: C
authors.lastname: Ibuki
authors.forename: Kunio
authors.initials: K
authors.lastname: Tanaka
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Kusama
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Seino
authors.forename: Kazuo
authors.initials: K
authors.lastname: Munakata
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Mizuno
mesh_terms: D000214:Acyl Coenzyme A / Q000627:therapeutic use*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D017558:Elective Surgical Procedures; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006335:Heart Injuries / Q000517:prevention & control*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000628:therapy*; D019990:Perioperative Care / Q000379:methods; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000214:Acyl Coenzyme A; D005464:Fluorobenzenes; D011743:Pyrimidines; D013449:Sulfonamides; C008047:3-hydroxy-3-methylglutaryl-coenzyme A; D000068718:Rosuvastatin Calcium